

Tom Decroo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2971946/publications.pdf>

Version: 2024-02-01

111
papers

2,207
citations

270111

25
h-index

286692

43
g-index

115
all docs

115
docs citations

115
times ranked

3162
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. <i>International Health</i> , 2023, 15, 258-264.	0.8	1
2	Pretomanid for tuberculosis: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 31-42.	2.8	30
3	Community-Based ART Service Delivery for Key Populations in Sub-Saharan Africa: Scoping Review of Outcomes Along the Continuum of HIV Care. <i>AIDS and Behavior</i> , 2022, 26, 2314-2337.	1.4	7
4	Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan. <i>Tropical Medicine and International Health</i> , 2022, 27, 207-215.	1.0	2
5	Implications of bedaquiline-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 166-167.	4.6	0
6	Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2022, 27, 100299.	0.6	2
7	Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. <i>PLoS ONE</i> , 2022, 17, e0263759.	1.1	7
8	Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac029.	0.9	24
9	Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac037.	0.9	0
10	Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018. <i>AIDS Research and Therapy</i> , 2022, 19, .	0.7	5
11	Community health worker-led ART delivery improved scheduled antiretroviral drug refill among men who have sex with men in Lagos State, Nigeria. <i>International Health</i> , 2021, 13, 196-198.	0.8	4
12	Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 831-835.	1.3	9
13	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. <i>European Respiratory Journal</i> , 2021, 57, 2002250.	3.1	12
14	Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya. <i>International Health</i> , 2021, 13, 272-280.	0.8	8
15	Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab034.	0.4	2
16	How to bring residents' psychosocial well-being to the heart of the fight against Covid-19 in Belgian nursing homes? A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0249098.	1.1	49
17	Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1317-1320.	0.6	2
18	Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis. <i>AIDS Research and Therapy</i> , 2021, 18, 16.	0.7	13

#	ARTICLE	IF	CITATIONS
19	<i>Mycobacterium tuberculosis</i> <i>rrpB</i> mutations: emerging from the unknown. European Respiratory Journal, 2021, 58, 2100783.	3.1	9
20	Human rights: finding the right balance for rifampicin-resistant TB treatment. International Journal of Tuberculosis and Lung Disease, 2021, 25, 327-328.	0.6	0
21	Should treatment of low-level rifampicin mono-resistant tuberculosis be different?. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021, 23, 100240.	0.6	0
22	Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda. American Journal of Tropical Medicine and Hygiene, 2021, 105, 47-53.	0.6	0
23	Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis. European Respiratory Journal, 2021, , 2102124.	3.1	2
24	How Second-Line Injectable Drugs Work. Clinical Infectious Diseases, 2021, 72, e1167-e1168.	2.9	2
25	“I don’t know when he will be back” life-changing events challenge the community ART Group model—a qualitative research study, Tete, Mozambique. BMC Public Health, 2021, 21, 2004.	1.2	0
26	Long-term retention and predictors of attrition for key populations receiving antiretroviral treatment through community-based ART in Benue State Nigeria: A retrospective cohort study. PLoS ONE, 2021, 16, e0260557.	1.1	3
27	World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. International Journal of Antimicrobial Agents, 2020, 55, 105822.	1.1	19
28	Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study. International Health, 2020, 12, 95-100.	0.8	6
29	Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe’s national antiretroviral therapy programme between 2012 and 2015. PLoS ONE, 2020, 15, e0222309.	1.1	21
30	Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. Journal of Clinical Medicine, 2020, 9, 55.	1.0	34
31	Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. Respiratory Medicine, 2020, 161, 105844.	1.3	26
32	Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study. PLoS ONE, 2020, 15, e0237355.	1.1	8
33	District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health. BMC Research Notes, 2020, 13, 393.	0.6	3
34	Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. PLoS ONE, 2020, 15, e0238016.	1.1	6
35	Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. PLoS ONE, 2020, 15, e0237787.	1.1	7
36	Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. International Journal of Infectious Diseases, 2020, 100, 357-365.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Management of falsepositive rifampicin resistant Xpert MTB/RIF – Authors' reply. Lancet Microbe, The, 2020, 1, e239.	3.4	0
38	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. PLoS ONE, 2020, 15, e0233500.	1.1	16
39	First-line tuberculosis treatment with double-dose rifampicin is well tolerated. International Journal of Tuberculosis and Lung Disease, 2020, 24, 499-505.	0.6	11
40	Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. Lancet Microbe, The, 2020, 1, e74-e83.	3.4	35
41	High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1578-1579.	2.5	8
42	Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi. Journal of Clinical Medicine, 2020, 9, 1873.	1.0	8
43	Knowledge transmission, peer support, behaviour change and satisfaction in post Natal clubs in Khayelitsha, South Africa: a qualitative study. Reproductive Health, 2020, 17, 107.	1.2	6
44	Tuberculosis treatment: one-shot approach or cascade of regimens?. Lancet Respiratory Medicine,the, 2020, 8, e4-e5.	5.2	7
45	Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family. Tuberculosis, 2020, 122, 101922.	0.8	6
46	Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. International Journal of Tuberculosis and Lung Disease, 2020, 24, 329-339.	0.6	26
47	Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV –Treat All–in Zimbabwe. PLoS ONE, 2020, 15, e0240865.	1.1	13
48	Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1443-1446.	0.6	6
49	Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. International Journal of Tuberculosis and Lung Disease, 2020, 24, 763-769.	0.6	3
50	Title is missing!. , 2020, 15, e0222309.		0
51	Title is missing!. , 2020, 15, e0222309.		0
52	Title is missing!. , 2020, 15, e0222309.		0
53	Title is missing!. , 2020, 15, e0222309.		0
54	Injectables™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0

#	ARTICLE	IF	CITATIONS
55	Injectables™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
56	Injectables™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
57	Injectables™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
58	Title is missing!. , 2020, 15, e0233500.		0
59	Title is missing!. , 2020, 15, e0233500.		0
60	Title is missing!. , 2020, 15, e0233500.		0
61	Title is missing!. , 2020, 15, e0233500.		0
62	Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study. Global Health Action, 2019, 12, 1646024.	0.7	6
63	Viral load detection and management on first line ART in rural Rwanda. BMC Infectious Diseases, 2019, 19, 8.	1.3	15
64	“œI take my pills every day, but then it goes up, goes down. I don’t know what’s going on” Perceptions of HIV virological failure in a rural context in Mozambique. A qualitative research study. PLoS ONE, 2019, 14, e0218364.	1.1	6
65	ARTadherence clubs in the Western Cape of South Africa: what does the sustainability framework tell us? A scoping literature review. Journal of the International AIDS Society, 2019, 22, e25235.	1.2	17
66	Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study. International Health, 2019, 11, 520-527.	0.8	7
67	Operational research: did health systems in Sierra Leone recover after the 2014-15 Ebola outbreak?. F1000Research, 2019, 8, 792.	0.8	4
68	Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1733-1734.	1.3	2
69	Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1450-1461.	0.6	4
70	Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: Experiences from Nasarawa State, Nigeria. PLoS ONE, 2018, 13, e0209477.	1.1	17
71	Blended SORT-IT for operational research capacity building: the model, its successes and challenges. Global Health Action, 2018, 11, 1469215.	0.7	6
72	Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. International Journal of Tuberculosis and Lung Disease, 2018, 22, 239-245.	0.6	65

#	ARTICLE	IF	CITATIONS
73	Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. <i>Malaria Journal</i> , 2017, 16, 81.	0.8	23
74	High mortality in non-Ebola virus disease cases: need to provide timely and effective care. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1021-1022.	4.6	1
75	Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs. <i>International Health</i> , 2017, 9, 206-214.	0.8	26
76	Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study. <i>BMJ Open</i> , 2017, 7, e016800.	0.8	45
77	What was the effect of the West African Ebola outbreak on health programme performance, and did programmes recover?. <i>Public Health Action</i> , 2017, 7, 1-2.	0.4	11
78	Mortality among PCR negative admitted Ebola suspects during the 2014/15 outbreak in Conakry, Guinea: A retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0180070.	1.1	5
79	Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold. <i>BMC Infectious Diseases</i> , 2017, 17, 674.	1.3	8
80	Operational Research during the Ebola Emergency. <i>Emerging Infectious Diseases</i> , 2017, 23, 1057-1062.	2.0	6
81	Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care. <i>PLoS ONE</i> , 2016, 11, e0166444.	1.1	40
82	Psychological Distress among Ebola Survivors Discharged from an Ebola Treatment Unit in Monrovia, Liberia – A Qualitative Study. <i>Frontiers in Public Health</i> , 2016, 4, 142.	1.3	94
83	Ebola Virus in Breast Milk in an Ebola Virus-Positive Mother with Twin Babies, Guinea, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 759-760.	2.0	36
84	Dangerous crossing: demographic and clinical features of rescued sea migrants seen in 2014 at an outpatient clinic at Augusta Harbor, Italy. <i>Conflict and Health</i> , 2016, 10, 14.	1.0	41
85	Lessons learnt from TB screening in closed immigration centres in Italy. <i>International Health</i> , 2016, 8, 324-329.	0.8	13
86	Delivery of an Ebola Virus-Positive Stillborn Infant in a Rural Community Health Center, Sierra Leone, 2015. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 417-419.	0.6	39
87	Tuberculosis among indigenous municipalities in Mexico: analysis of case notification and treatment outcomes between 2009 and 2013. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 39, 32-37.	0.6	0
88	Trends in tuberculosis notification and treatment outcomes in prisons: a country-wide assessment in El Salvador from 2009-2014. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 39, 38-43.	0.6	6
89	Social Consequences of Ebola Containment Measures in Liberia. <i>PLoS ONE</i> , 2015, 10, e0143036.	1.1	161
90	The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a MÃ©decins Sans FrontiÃ©res Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014. <i>Journal of Infectious Diseases</i> , 2015, 212, 1752-1758.	1.9	88

#	ARTICLE	IF	CITATIONS
91	Patients struggle to access effective health care due to ongoing violence, distance, costs and health service performance in Afghanistan. <i>International Health</i> , 2015, 7, 169-175.	0.8	35
92	Favipiravirâ€”a prophylactic treatment for Ebola contacts?. <i>Lancet, The</i> , 2015, 385, 2350.	6.3	12
93	Community-Based ART Resulted in Excellent Retention and Can Leverage Community Empowerment in Rural Lesotho, A Mixed Method Study. <i>HIV/AIDS Research and Treatment: Open Journal</i> , 2015, 2, 44-50.	0.2	21
94	Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. <i>Eurosurveillance</i> , 2015, 20, .	3.9	16
95	Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. <i>Eurosurveillance</i> , 2015, 20, .	3.9	35
96	Post-Traumatic Stress Reactions in Ebola Virus Disease Survivors in Sierra Leone. <i>Emergency Medicine: Open Access</i> , 2015, 05, .	0.1	38
97	A Qualitative Assessment of a Community Antiretroviral Therapy Group Model in Tete, Mozambique. <i>PLoS ONE</i> , 2014, 9, e91544.	1.1	59
98	Sustainability of a communityâ€”based antiâ€”retroviral care delivery model â€” a qualitative research study in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2014, 17, 18910.	1.2	51
99	Fourâ€”year retention and risk factors for attrition among members of community <sc>ART</sc> groups in <sc>T</sc>ete, <sc>M</sc>ozambique. <i>Tropical Medicine and International Health</i> , 2014, 19, 514-521.	1.0	98
100	Adapting a community-based ART delivery model to the patientsâ€™ needs: a mixed methods research in Tete, Mozambique. <i>BMC Public Health</i> , 2014, 14, 364.	1.2	48
101	Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for success. <i>The Lancet Global Health</i> , 2014, 2, e262-e263.	2.9	4
102	Describing readmissions to an Ebola case management centre (CMC), Sierra Leone, 2014. <i>Eurosurveillance</i> , 2014, 19, 20924.	3.9	27
103	Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. <i>Eurosurveillance</i> , 2014, 19, .	3.9	76
104	Utilization of and Barriers to HIV and MCH Services among Community ART Group Members and Their Families in Tete, Mozambique. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-8.	0.3	4
105	Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. <i>International Health</i> , 2013, 5, 169-179.	0.8	136
106	Are Expert Patients an Untapped Resource for ART Provision in Sub-Saharan Africa?. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-8.	0.3	38
107	Getting HIV Treatment to the Most People. <i>Science</i> , 2012, 337, 298-300.	6.0	22
108	Distribution of Antiretroviral Treatment Through Self-Forming Groups of Patients in Tete Province, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e39-e44.	0.9	167

#	ARTICLE	IF	CITATIONS
109	Burden and outcome of HIV infection and other morbidities in health care workers attending an Occupational Health Program at the Provincial Hospital of Tete, Mozambique. <i>Tropical Medicine and International Health</i> , 2011, 16, 1450-1456.	1.0	3
110	Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2009, 12, 6-6.	1.2	43
111	Continuous surveillance of drug-resistant TB burden in Rwanda: a retrospective cross-sectional study. <i>International Health</i> , 0, , .	0.8	1